Prosensa

Prosensa was a Dutch biotechnology company headquartered in Leiden and focused on the discovery, development, and potential commercialization of RNA-modulating medicines for serious genetic diseases. Its work concentrated on disorders with substantial unmet medical need, particularly neuromuscular and neurodegenerative conditions. Duchenne muscular dystrophy (DMD) became the company’s central therapeutic area, although its technology platform was also directed toward myotonic dystrophy, Huntington’s disease, and other genetic indications. The company began operations in 2002 and built its technology base through collaboration with academic researchers and clinical specialists. In 2003, Prosensa entered an exclusive licensing arrangement with Leiden University Medical Center for RNA-modulation technology based on exon skipping. Exon skipping seeks to alter the way genetic instructions are processed so that cells can produce a shortened but potentially functional version of a disease-related protein. In DMD, the approach was intended to help restore production of dystrophin, a protein absent or severely deficient in patients with many forms of the disease. Prosensa developed a portfolio of antisense oligonucleotide candidates. Its lead program, drisapersen, was designed for a subset of DMD patients whose mutations could potentially be addressed by skipping exon 51 of the dystrophin gene. The candidate progressed through clinical development and reached Phase III testing. Prosensa also advanced PRO044, PRO045, and PRO053 into clinical development, while PRO052 and PRO055 remained in advanced preclinical development. The company’s PROSPECT program explored multiple-exon skipping, an approach intended to address rarer dystrophin mutations, initially involving the exon 10-to-30 region. Alongside drug development, Prosensa conducted a natural-history study of DMD. The study enrolled 269 patients across the United States, Europe, and Latin America and was intended to improve understanding of disease progression, support clinical-trial design, identify safety and progression biomarkers, and provide comparative information for future studies where conventional controlled trials could be difficult to conduct. Prosensa became a publicly traded biotechnology company through a 2013 Nasdaq initial public offering. Its corporate and clinical trajectory was subsequently shaped by the uncertain efficacy and safety profile of drisapersen. In 2014, a shareholder filed a proposed class action in the United States alleging that investors had been misled about the prospects and near-term commercial potential of the DMD program. The company’s strategic position changed decisively when BioMarin Pharmaceutical agreed in November 2014 to acquire Prosensa for consideration of up to $840 million. The transaction was completed in 2015, and Prosensa ceased to operate as an independent public biotechnology company. The drisapersen program did not ultimately reach approval. Although the United States Food and Drug Administration accepted a New Drug Application in June 2015, the agency rejected the application in January 2016, citing concerns that included toxicity and an insufficient benefit-risk profile. In May 2016, BioMarin discontinued the clinical and regulatory development of drisapersen and ended Phase 2 development of BMN 044, BMN 045, and BMN 053, the BioMarin-designated successors to Prosensa’s PRO044, PRO045, and PRO053 programs. Prosensa is therefore best understood as a defunct, acquired biotech company whose principal legacy was the advancement of exon-skipping research for DMD and related genetic disorders rather than an approved commercial product.

Prosensa commenced operations in 2002 in Leiden, the Netherlands, as a biotechnology company dedicated to RNA-modulating therapeutics. Its strategy was based on the premise that RNA processing could be manipulated to compensate for disease-causing genetic mutations. Rather than developing conventional small-molecule medicines, the company pursued antisense oligonucleotides and related exon-skipping approaches for rare inherited disorders. A key foundation for the business was established in 2003, when Prosensa obtained an exclusive license from Leiden University Medical Center for proprietary RNA-modulation technology. The license supported work in Duchenne muscular dystrophy, other neuromuscular diseases, and selected indications outside the neuromuscular field. Prosensa worked with academic institutions, patient organizations, clinicians, and disease experts internationally, reflecting the specialized nature of rare-disease research and the need for carefully characterized patient populations. DMD became Prosensa’s principal development focus. The disease is a severe inherited neuromuscular disorder associated with progressive muscle degeneration and mutations in the dystrophin gene. Prosensa’s exon-skipping technology aimed to alter dystrophin messenger RNA so that some patients could produce a shorter dystrophin protein with potential functional value. Drisapersen was the company’s leading candidate and was developed for patients with mutations potentially addressable through exon 51 skipping. It advanced through clinical testing and completed Phase III trials. Prosensa maintained a broader pipeline around the DMD platform. PRO044, PRO045, and PRO053 entered clinical development, while PRO052 and PRO055 reached advanced preclinical work. The PROSPECT program investigated multiple-exon skipping, initially targeting the exon 10-to-30 region of the dystrophin gene. According to the company’s stated development rationale, this approach could potentially cover a further 5% to 13% of the DMD population, although it remained preclinical and did not become an approved therapy. The company also invested in disease characterization. Its DMD natural-history study enrolled 269 participants in the United States, Europe, and Latin America. The study was designed to document disease progression, help researchers design subsequent clinical trials, evaluate biomarkers related to safety and progression, and create comparative data for rare mutation groups in which traditional controlled trials may be impractical. Prosensa entered the public markets in 2013 through a Nasdaq initial public offering. The listing exposed the company to public-market expectations surrounding clinical milestones and the commercial prospects of drisapersen. In 2014, an American shareholder brought a proposed class action in New York, alleging that investors had been misled in connection with the IPO and the expected development and royalty prospects of the DMD drug program. The available reference material describes the allegations but does not establish a final court outcome. The company’s independent corporate life ended through a transaction with BioMarin Pharmaceutical. In November 2014, BioMarin agreed to acquire Prosensa for consideration of up to $840 million. The acquisition was completed in 2015, after which Prosensa’s personnel, assets, and drug-development programs were integrated into BioMarin’s rare-disease operations. Drisapersen was submitted to the United States FDA, which accepted the New Drug Application in June 2015. The regulatory outcome was unfavorable. In January 2016, the FDA rejected drisapersen, with toxicity and questions concerning the overall benefit-risk balance among the central issues. In May 2016, BioMarin discontinued both the clinical and regulatory development of drisapersen and Phase 2 studies of BMN 044, BMN 045, and BMN 053, which had previously carried the Prosensa designations PRO044, PRO045, and PRO053. Prosensa consequently remained a defunct brand and corporate entity, while its main historical contribution was the clinical advancement of exon-skipping research in DMD and the broader rare-disease RNA-therapeutics field.

• 2016

  FDA rejects drisapersen

  [1]Prosensaen.wikipedia.org

  The FDA rejected drisapersen, citing toxicity and an unfavorable or insufficiently established benefit-risk profile.

• 2016

  BioMarin ends related clinical programs

  [1]Prosensaen.wikipedia.org

  BioMarin discontinued drisapersen development and Phase 2 programs corresponding to PRO044, PRO045, and PRO053.

• 2015

  Acquisition completed

  [1]Prosensaen.wikipedia.org

  BioMarin completed the acquisition, ending Prosensa’s status as an independent company.

• 2015

  Drisapersen application accepted by FDA

  [1]Prosensaen.wikipedia.org

  The FDA accepted the New Drug Application for drisapersen.

• 2014

  BioMarin announces acquisition agreement

  [1]Prosensaen.wikipedia.org

  BioMarin agreed to acquire Prosensa for consideration of up to $840 million.

• 2013

  Nasdaq initial public offering

  [1]Prosensaen.wikipedia.org

  Prosensa became a publicly traded biotechnology company through a Nasdaq IPO.

• 2003

  Exclusive LUMC technology license

  [1]Prosensaen.wikipedia.org

  Prosensa obtained an exclusive license from Leiden University Medical Center for exon-skipping and RNA-modulation technology.

• 2002

  Prosensa begins operations

  [1]Prosensaen.wikipedia.org

  Prosensa commenced operations in Leiden as a biotechnology company developing RNA-modulating treatments for genetic diseases.

Rare-disease biotechnology focused on RNA modulation and exon-skipping therapies for neuromuscular and neurodegenerative disorders.

• Antisense oligonucleotide; exon-skipping therapy

  Drisapersen

  Drisapersen was Prosensa’s lead investigational treatment for a genetically defined subset of patients with Duchenne muscular dystrophy. It was designed to skip exon 51 of dystrophin messenger RNA, potentially enabling production of a shortened dystrophin protein. The candidate completed Phase III testing and its United States New Drug Application was accepted in 2015. The FDA rejected the application in January 2016, and BioMarin discontinued the program several months later. Drisapersen never received United States approval.

• Antisense oligonucleotide; exon-skipping therapy

  PRO044

  PRO044 was one of Prosensa’s clinical-stage DMD exon-skipping candidates. The program was later designated BMN 044 after the acquisition by BioMarin. BioMarin discontinued its Phase 2 development in 2016. The available reference material does not provide sufficient detail to establish a commercial launch or an approved indication.

• Antisense oligonucleotide; exon-skipping therapy

  PRO045

  PRO045 was a clinical-stage Prosensa candidate directed at Duchenne muscular dystrophy through exon-skipping technology. Following the acquisition, it was referred to as BMN 045 by BioMarin. Its Phase 2 development was discontinued in 2016, and it did not become a marketed medicine.

• Antisense oligonucleotide; exon-skipping therapy

  PRO053

  PRO053 was another Prosensa clinical-development program for DMD. BioMarin renamed the program BMN 053 after acquiring Prosensa and later stopped its Phase 2 development in 2016. No commercial product resulted from the program.

• Preclinical exon-skipping therapy

  PRO052

  PRO052 was part of Prosensa’s advanced preclinical DMD pipeline. It was intended to extend the company’s exon-skipping platform to additional dystrophin mutations, but the available reference does not document clinical advancement, approval, or commercialization.

• Preclinical exon-skipping therapy

  PRO055

  PRO055 was an advanced preclinical candidate in Prosensa’s DMD portfolio. It represented an effort to broaden mutation coverage through the company’s RNA-modulation platform. No approved or marketed product emerged from the program according to the available reference.

• Preclinical multi-exon-skipping platform

  PROSPECT

  PROSPECT was a preclinical program exploring multiple-exon skipping for rarer dystrophin mutations, initially focusing on the exon 10-to-30 region. Prosensa estimated that the approach could potentially address an additional 5% to 13% of the DMD population, but it did not become a commercial therapy.

• 2014

  Shareholder class-action allegations concerning the IPO

  An American shareholder filed a proposed class action in New York alleging that Prosensa had misled investors during its 2013 Nasdaq IPO about the prospects, expected timing, and potential economic returns of its Duchenne muscular dystrophy drug program. The available material records the allegations but does not establish a final judgment or settlement.

  Source

Read more

• 2016

  Discontinue drisapersen and related programsOther

  Background

  The FDA rejected drisapersen after reviewing the candidate’s efficacy and safety profile, and BioMarin reassessed the remaining Prosensa-derived pipeline.

  Action taken

  BioMarin ended drisapersen’s clinical and regulatory development and stopped Phase 2 studies of BMN 044, BMN 045, and BMN 053.

  Aftermath

  The decision ended the principal clinical programs inherited from Prosensa and removed the prospect of a Prosensa-derived commercial DMD product.

  Source

• 2014

  Agree to acquisition by BioMarinM&A

  Background

  Prosensa had a late-stage DMD candidate and a broader exon-skipping pipeline but faced the capital and clinical risks associated with independent rare-disease development.

  Action taken

  Prosensa agreed to be acquired by BioMarin for consideration of up to $840 million.

  Aftermath

  The transaction was completed in 2015 and Prosensa ceased to operate as an independent company.

  Maximum acquisition consideration. Up to $840 million (2014 acquisition agreement)

  Source

• 2003

  License exon-skipping technology from LUMCStrategy

  Background

  Prosensa needed a proprietary scientific platform for developing RNA-modulating treatments in rare genetic diseases.

  Action taken

  The company entered an exclusive licensing agreement with Leiden University Medical Center covering exon-skipping technology and related applications.

  Aftermath

  The license became the scientific foundation for Prosensa’s DMD-focused pipeline and its broader RNA-modulation strategy.

  Source

1. 1Prosensaen.wikipedia.org